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Sary Pyroidno-4-iodotamoxifen (idoxifene) is a new non-steroidal antioestrogen currently undergoig
phase I clnical evaluation. Using idoxifene and tamoxifen and two additional analogues of tamoxifen
(3-hydroxytamoxifen and 4-iodotamoxifen) and the imidazole-based calmoduin inhibitor, anmidazolim, a
strong positive correlation (r2>0.95) was observed between cytotoxicity and inhibition of cahodulin-
dependent cyclic AMP phosphodiesterase (e.g. mean IC", across four human ovaran carcnoma cell lnes of
4.5 pm for idoxifene and 6.3 pM for tamoxifen). Using two parent human ovarian carcinoma cel lines (41M
and CHI; both oestrogen receptor negative) in which acquired resstance to doxorubicin or cisplatin has been
generated, we have determined the ability of idoxifene to overcme resistance in these lnes. At a non-toxic
concentration of 2P, idoxifene appeared at kast as effective as the clnically used multidrug resistance
modis vpamil and tamoxifen in overcoming doxorubicin resistance in two acquired resistant cell lnes
shown to overexres the P-170 efflux glycoprotein. Non-cross-resistance between ciplatin and idoxifene was
observed in two acquired resstant cell lnes possessing contrasting nsm of resistance to cisplatin
(41McisR6 reduced drug tansport and CHIcisR6 resistance mediated at the level ofDNA). In one of four cell
lines (CHI), synergism between idoxifene and cispLain was observed by median effect analysis. However, with
the 41M and its 6-fold cisplatin-resistant variant, antagonism was observed. These observations made by
median effect analysis appeared to be unrelated to platinum uptake or removal of platinum-induced DNA
interstrand cross-nk s. These in vitro data suggest that idoxifene may be usefully combined with doxorubicin
in the cinical setting, but caution should be exercised in combining it with cisplatin in the treatment ofcertain
tumours.
The clinical effectiveness ofthe widely used anti-cancer drugs,
cisplatin [cis-diamminedichloroplatinum (II)] and doxo-
rubicin, is commonly limited by tumour resistance, either
present at the outset or acquired during chemotherapy.
Resistance to cisplatin has been shown to be mediated
through one or more of reduced drug influx, increased intra-
cellular detoxification by glutathione and/or metallothioneins
or increased removal of DNA-platinum adducts (see Mc-
Keage & Kelland, 1993, for a review). In contrast, resistance
to doxorubicin is commonly attributable to enhancd drug
efflux through either the P-170 transmembrane glycoprotein
(Kartner et al., 1983) or the more recently described 190 kDa
multidrug resistance-associated protein (MRP) (Cole et al.,
1992).
In recent years, a number of agents have been used in
attempts to circumvent drug resistance. One agent that has
featured in studies of both doxorubicin and cilatin resist-
ance has been the extensively used antioestrogen tamoxifen.
For example, tamoxifen is one of many diverse agents shown
to inhibit P-glycoprotein (see Futscher & Dalton, 1993, for a
review). Furthermore, McClay and colleagues have recently
shown a highly synergistic interaction between tamoxifen and
cisplatin in human malignant melanoma cells (McClay et al.,
1992, 1993a) and a human ovarian carcinoma and small-cell
lung cancer cell line (McClay et al., 1993b). Synergisi anti-
proliferative activity of tamoxifen and cisplatin has also been
shown using a primary ovarian tumour (Scambia et al.,
1992). At present, the underlying mechanism(s) responsible
for the synergy is unclear. As well as its effects on the
oestrogen receptor, tamoxifen has been shown to exert
inhibitory effects on calmodulin (Lam, 1984) and protein
kinase C (O'Brian et al., 1985). Whether these effects con-
tribute to the therapeutic utility of taxoxifen is uncertain,
although the drug has been reported to produce some re-
sponses in a small number of oestrogen receptor-negative
tumours (Breast Cancer Trials Committee, 1987). Interest-
ingly, the calmodulin antagonist W-7 [(N-6aminohexyl)-5-
chloro-l-naphthalenesulphonamide] has been shown to
increase cisplatin uptake in cisplatin-resistant cells (Kikuchi
et al., 1990), and another calmodulin inhibitor,
trifluoperazine, has been shown to potentiate cisplatin
cytotoxicity (Perez et al., 1992a).
Pyrrolidino-4-iodotamoxifen (idoxifene) is one of a series
of recently synthesised 4-substituted analogues of tamoxifen
(McCague et al., 1989). It has also been shown that idoxifene
has a greater ability to inhibit calmodulin-dependent cyclic
AMP phosphodiesterase than tamoxifen itself (IC50 of 1.41LM
vs 6.75 jpM for tamoxifen) (Rowlands et al., 1990). Idoxifene
is currently undergoing phase I clinical evaluation in ad-
vanced breast cancer (Quigley et al., 1993).
Tlhe purposes of this study were 3-fold. Initially, using a
series of tamoxifen analogues of known inhibitory constants
for calmodulin, the effect of increasing calmodulin inhibition
on cytotoxicity against four human ovarian carcnoma cell
lines was determined. Secondly, we have determined the com-
parative ability of idoxifene, tamoxifen and verapamil to
circumvent acquired doxorubicin istanc in two newly
established doxorubicin-resistant human ovarian carcinoma
cell lines. Thirdly, we have attempted to potentiate the
cytotoxicity ofcisplatin by idoxifene in two pairs (parent and
acquired cisplatin-resistant variant) of human ovarian car-
cinoma cell lines with distint mechanisms of reistance to
cisplatin: 4lMcisR6, resistat mainly through reduced drug
transport; and CHIcisR6, resistant through effects mediated
at the DNA level (Kelland et al., 1992a; Loh et al.,
1992).
Materials and mehod
Drugs and chemicals
The structures of tamoxifen and the various analogues of
tamoxifen used are illustrated in Figure 1. Idoxifene and
4-iodotamoxifen were synthesised according to McCague et
al. (1989), and 3-hydroxytamoxifen, also in clinical evalua-
tion under the name of droloxifene (Bruning, 1992), by
Foster et al. (1985). Cisplatin was synthesised by and
obtained from the Johnson Matthey Technology Centre
(Reading, Berkshire, UK). Calmidazolium (R24571),
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final concentration of ethanol (0.5%) in growth medium had
no inhibitory effect on cell growth. Cisplatin was dissolved in
0.9% saline at 500gm.
The cytotoxicities of the drugs were assessed using the
SRB assay, and this was performed as described previously
(Kelland et al., 1992b). In the combination experiments with
cisplatin and idoxifene, cells were concomitantly exposed to
different concentrations of cisplatin, and idoxifene at the
non-toxic dose, for 96 h. For the combination experiments
involving doxorubicin, the resistance modifiers (verapamil
6 9M, tamoxifen 4pM, idoxifene 2pAM) were added 2 h prior
to the doxorubicin.
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(idoxifene)
CI
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~CH2
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Median effect analysis
The cytotoxicity data of idoxifene, cisplatin and combina-
tions of these drugs in constant molar ratios were analysed
by median effect analysis (Chou & Talalay, 1984). Briefly, the
analysis compares the effects of drug combinations to the
effects ofindividual drugs across the entire dose-effect range.
Cytotoxicity data were then fitted to regression lines, and the
concentration of each drug which produced a given level of
cytotoxicity (fractional effect, Fa) alone or in combination
was determined. Combination index (CI) for a given Fa was
calculated as:
CI = d' + td D-1 +D2
where DI and D2 are the doses of drugs 1 and 2, which by
themselves produce a given Fa (i.e. IC5o); d' and d2 are the
doses which produce the same Fa in combination. CI= I
indicates zero interaction (additive cytotoxicity), CI <I
indicates synergy and CI> 1 indicates antagonism (Chou
computer program, Biosoft).
Calmidazolium (R 24571)
Fgme 1 Structures of tamoxifen and the vanous analogues
used.
verapamil and sulphorhodamine B (SRB) were obtained from
Sigma.
Cell lines
Two 'parent' human ovarian carcinoma cell lines (41M and
CHI) were used in this study-, their biological properties have
been described previously (Hills et al., 1989). Both cell lnes
were essentially negative for the expron of oestrogen
receptors (possing <10fmolmg-' cytosol protein) (Hills
et al., 1989).
Cisplatin acquired rstant vanants to these cell lines were
generated as described previously (Kelland et al., 1992a).
Doxorubicin acquired resistant cell lines (4lMdoxR and
CHldoxR) were establshed by exposing the same two parent
lines to increasing concentrations of doxorubicin (from 1 nm
to 500 nM) ovrer 8 months for CHI cells and 17 months for
41M cells. During the course of th experiments resistance
was maintained in the absnce of further exposure to doxo-
rubicin.
All cell lines were grown as monolayers in Dulbecco's
modified Eagle medium (DMEM) supplemented with 10%
heat-iactivated fetal calf serum (Imperial Laboratores,
Andover, UK), 50 gml-' gentamic 2.5 jg ml-' ampho-
tericin B, 2 mM L-glutmie 10 jag ml- insulin and
0.5 jgmml' hydrocorisone in a 10% carbon dioxide, 90%
air atmosphere. There was no contamination with Myco-
plama throughout the course of the study.
Assssment ofcytotoxicity
Tamoxifen and the analogues of tamoxifen were dissolved
immediately before use in absolute ethanol at 20 mM. The
Intracelhllarplatiwn accwmdation
The experimental conditions and method of determination of
intracellular platinum content using flamees atomic absorp-
tion spectrometry (Perkin-Elmer 1 lOOB and HGA 700,
Beaconsfied UK) were as described previously (Loh et al.,
1992).
Imnunwblottingfor P-170 glycoprotein
Exponentially growing cells were washed twice with
phosphate-buffered saline (PBS), scraped and harvested with
PBS containing phenyhlethylsulphonylfluoride (PMSF) at
10Opg ml-' at 4C and centrifuig (1,000 r.p.m., 60g,5m,
room temperature). Cell pellets were then lysed in 1 mM Tris
(pH 7.4) containing l00 agml-' PMSF and left at 4-C for
1 h. Nucki and unbroken cells were removed by centrifuga-
tion (450g. 10 mmn, 4C). Cell membranes were obtained
from the resultant supernatant, which was centrifuged
(60,000g, 1 h, 4-C). Membrane proteins (60pg per well) were
resolved by eectrophoresis in 6% polyacrylamide in the
presence of sodium dodecyl sulphate (SDS-PAGE), and
electroblotted onto nitrocellulose filter as described by Tow-
bin et al. (1979), at 300mA for 2h. The filter was first
blocked overnight at 4-C in buffer (pH 7.6) containing
154 mM sodium chloride, 10mM Tris, 0.5% Casein Ham-
mersten (BDH) and 0.02% thimerosal, and then exposed to
the monoclonal antibody (C219; Centocor, USA) diluted
1:500 in blockcing buffer for 3 h. Finally, the fitr was
exposed to horseradish peroxidase-labeled secondary
antibody (Amersham) for 1 h, diluted 1:1,000 in blocking
buffer before detecting with enhanced chemiluinescence
(ECL) reagents (Amersham) and exposng to autoradiog-
raphy film (Hyperfilm-ECL, Amersham). The doxorubicin-
resistant human small-cell lung line LX4 (kindly provided by
P. Twentyman and previously shown to overexpres the P-
170 glycoprotein; Twentyman et al., 1986) was used as a
positive control.
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Determination ofDNA interstrand cross-link repair by alkalue
ehution
DNA interstrand cross-linking was assessed by alkalie elu-
tion, as described by Kelland et al. (1992a). Briefly, after 2 h
exposure to cisplatin, cells were washed with PBS at 37C
and further incubated with idoxifene (2pM) for 0, 5 and 24 h.
For cells without idoxifene, medium was added. Cross-
linking index was calculated using the following formula as
described previously (Roberts & Friedlos, 1987):
Cross-linking index = (V1 ro-1) I xP
where r and ro are the fractions of `4C-labelled DNA for
treated versus control cells remaining on the filter when 50%
of 3H-labelled DNA is retained on the filter and P is the rad
equivalent (517). Results were then expressed as the cross-
linkling index versus the time when cisplatin was removed and
idoxifene was introduced during the repair period.
Statistical analysis
Where appropriate, statistical significe was tested using a
two-tailed Student's f-test; a P-value <0.05 was considered
significant.
Reis
Initially, the cytotoxicity of tamoxifen, three analogues (3-
hydroxytamoxifen, 4-iodotamoxifen and idoxifene) and the
calmodulin antagonist camidazolum (R24571) was deter-
mined against four human ovarian carcinoma cell lines, 41M
and CHI and their acquired cisplatin-resistant variants
41McisR6 and CHIcisR6. The results (Figure 2a for 41M
lnes and Figure 2b for CHI lines) showed a strong correla-
tion between the inhibition of calmodulin-dependent cyclic
AMP phosphodiestase [vahls taken from previous deter-
minations (Rowlands et al., 1990) except for 3-hydroxy-
tamoxifen, for which the IC50 vahle is 139M ± 1.5
(unpublished data)] and cytotoxicty. For example, idoxifene
(calmodulin IC5o 1.4gAM) was more cytotoxic (mean IC5o
across the four cell lines of 4.5gM) than tamoxifen (mean
IC,, of 6.3pM; calmodulin IC,o of 6.75gM). Correlation
coefficients were greater than 0.95 for all four cell lines.
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Fugwe 2 The iip w lu in inhibition by
tamoxifen and the various anal, and their cytotoxicities in
(a) 41M (0) and 41McisR6 (-) and (b) CHI (A) and CHlcisR6
(A). Inhibitio of da' t cydic AMP phosphodi-
esterase was min usng 2,8HJcyc3,5AMP as sub-
strate as desaibed in Rowlands et at. (1990). 1 = R24571;
2 =idoxifene; 3 =4-iodotamoxifen; 4 =tamoxifen, 5 = 3-
hydroxytamoxifen
Activity ofidoxifene against acquireddoxorubicin-resistant cell
lines
Acquired resistance to doxorubicin has been established in
two human ovarian carcinoma cell ines, 41M and CHI.
Reistance factors (IC resistant/IC,, parent) to doxorubicin
of approximately 7 and 90 were obtained for 41M and CHI
cells rptely. As one ofthe objectives ofthe study was to
determine the effectiveness of idoxifene in circumventing
doxorubicin-induced multidrug resistance, we have deter-
mined the klvels of P-170 glycoprotein in the paired cell lines
by immunoblotting using the C219 monoclonal antibody.
Figure 3 shows that both doxorubicin-resiant sublines
overexpressed the P-170 glycoprotein compared with their
parent line. Elevation of P-170 levels was even apparent in
the 41M resistant line (4lMdoxR), which was seled at a
relatively low level (7-fold) of reistance. The previously
reported P-170-positive doxorubicin-resistant human small-
cell lung cancer line LX4 was included as a positive control.
Additionally, both resistant lines also showed cross-resistance
to other drugs previously shown to belong to the multidrug
resistance phenotype (e.g. TaxooL vinblastin) (data not
shown).
In preliminary experiments, the highest non-toxic concen-
tration of the resistance modifiers (<10% cell kill in any one
cell line; continuous drug exposure) was determined as 6 9AM
for verapamiL 4 JM for tamoxifen and 2 M for idoxifene.
These concentrations were then used in combination with
doxorubicin. The results are shown in Table I. While none of
the modifiers exerted any marked effect on the cytotoxicity of
doxorubicin to the parent cell lnes, all reduced the kvel of
doxorubicin reance in the acquired resstant ines.
Notably, idoxifene appeared at last as effective as the
cliniall used mutdrug reistance modfirs verapamil and
tamoxifen m overcoming doxorubicin reistance in these two
cel line models.
Activity ofidoxifene against acquired cisplatin-resistant cell
lines
Cross-resistance profiles for both the 41M and CHI pairs of
lnes to idoxifene, tamoxifen, 3-hydroxytamoxifen, 4-iodo-
tamoxifen and the potent imidazole-based cahmodulin in-
hibitor, camnidazolium, showed that, whereas both of the
acquired resistat cell lines exhibited around 6-fold rsistance
to cisplatin, no cross-resistance (istance factor <1) was
observed to all of the tamoxifen analogues and cabmi-
dazolium.
In view of previously reported synergistic effects between
cisplatin and tamoxifen (McClay et al., 1992, 1993a,b) we
have ivestigated the ability of idoxifene to potentiate the
cytotoxicity of cisplatin in these two paired cel lines by two
independent methods. Ftrsdy, cells were exposed concomi-
tantly (continuous exposure) to cisplatin at various concent-
rations and idoxifene at a fixed, highest non-toxic concentra-
tion (2pM) of idoxifene. Table II shows that, under these
conditions, idoxifene in the cytotoxicity ofcisplatin by
around 20% in the CH1 and CHlcisR6 cell lines (normalised
I '
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for any growth-inhibitory effect of idoxifene alone) but
decreased the cytotoxicity of cisplatin in the 41M pair of
lines; reistance factors to isplatin remained silar in the
presence or absence of idoxifene. None of these differences
reached statistical sig n. Secondly, the effects of com-
bining cisplatin and idoxifene were studied by median effect
analysis, a statistical method whereby the interaction between
two cytotoxic drugs may be evaluated using constant molar
ratios (based on relative IC,O values of the two drugs for each
cell line) according to published methods (Chou & Talalay,
1984). The results are shown in Table HI. Contrasting effects
were observed in the two pairs of lnes. While the drug
combination was antagonistic (combination index > 1) in the
41M and 41McisR6 cell lines, weak synergistic effects were
observed with CHI. A previous study (Perez et al., 1992b)
used sham combinations of cisplatin and carboplatin; CI
values at Fa = 0.5 ranged from 0.953 ± 0.289 to 0.935 ±
0.271. Therefore, the combination in the CHlcisR6 line is
additive.
We have begun to investigate the possible mechanistic
basis of the contrasting median effect analysis data for the
two pairs of cell lines. Figure 4 shows platinum accumulation
data for 4lMcisR6 (Figure 4a) and CHlcisR6 (Figure 4b)
following a 2 h exposure of cells to differing concentrations
of cisplatin either alone or in the presence of 2FM idoxifene.
Although reduced platinum uptake has previously been
shown to be a major contributing factor to the acquired
rsistance observed in 4lMcisR6 cells (Loh et al., 1992) and
marked antagonism (Table Ill) was observed with the
4lMcisR6 cells, there was no significant difference in
1 2 3 4 5 6 7
200K
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FAgWe 3 Western blot of P-glycoprotein in membrane sampes
of (1) LX4 (positive control), (2) 41M, (3) 4IMasR6, (4)
4lMdoxR, (5) CHI, (6) CHlcisR6 and (7) CHldoxR usin C219
monockoal antibody.
platinum accumulation in the pirsence of idoxifene.
Similarly, no difference in uptake was observed in the
CHlcisR6 cell line.
Our previous findings have shown that acquired istance
to cisplatin in the CHI/CHlcisR pair of lines is meiated at
the level of DNA, similar kvels of total platinum being
bound to DNA in the two cell ines following equiolar
concentrations of cisplatin (Kelland et al., 1992a). Figure 5
shows the rates offormation and rmoval ofplatinun-DNA
interstrand cross-linis (ISCs) as measured by alkalin filter
elution in the CHI and CHlcisR6 cell lines following a 2 h
exposure to cisplatin (251M) and allowing removal in the
presence (21M) or absence of idoxifene. The results show
that, while similar lvels of ISC are formed in the two cell
lnes immediately after the 2 h drug exposure (time zero), at
5 h post exposure more ISCs are present in the parent CHI
cells. Removal of cross-lnks was greater in the acquired
stant CHlcisR6 line (90% and 15% were removed at 2 h
versus 5h in CHlcisR6 and CHI respectively). Idoxifene,
however, did not markedly affect the rate of ISC removal in
either cell line.
Through the use of additional analogues of tamoxifen and
the potent imazole-based calmodulin inhibitor calmi-
dazolum, we have shown a strong positive correlation
between inhibition of calmodulin and in vitro cytotoxicty to
four oestrogen reptor-negative (<10 fmol mg' cytosolic
protein) human ovarian carcinoma cell lines. Tmese results
suggest that inhibition of calmoduln, an intraceular
calcium-binding protein that is known to play a key role in
regulating cell proliferation (Means, 1988), may be of impor-
tance in mediating the cytotoxic effects of idoxifene. As
calmodulin has been s as a possible target for new
chemotheaeutic strategies (Hait, 1987), futher variation of
the alkylaminoethoxy side chain of tamoxifen to obtain even
greater inhibition of calmodulin is in progress. Previous
studis with the same series of compounds have shown a
similar correlation between calmodulin inhibition and
cytotoxicty for oestrogen receptor-positive MCF-7 human
breast cancer cells but no such correlation for murine L1210
or rat Walker cells (Rowlands et al., 1990).
Tamoxifen has proven to be one of a number of diverse
agents capable of reversing P-170 glycoprotein-mediated
multidrug reistance (Ramu et al., 1984; Beck, 1991). One of
the most studied agents in this context in the cinic has been
the calcium channel blocker verapamil (Beck, 1991). Our
Table I Comparative effect of veapmil, tamoxifcn and idoxifene on doxo-
rubicin cytotoxicity in CHI/CHldoxR and 41M/4IMdoxR cells
96 h IC,, (nM)
41M 4lMdoxR t
96 IC3 (nM)
CHI CHldoxR RJ"
Doxorubicin 39 21 280 94 7.2 5.3 22 460 80 87
Doxorubicin
+6M verapamil 22 18 71 40 3.2 6.6±3 49 10 7.4
Doxorubicin
+4g tamoxifen 45 22 110 40 2.4 6.9 3 97 20 14
Doxorubicin
+2pm idoxifene 45 20 85 30 1.9 6.6 3 72 10 10.9
Valuesaremean±s.d. in threeexperiments. Rf esistanxfactor(IC3 resistant
line/IC53 parent line).
Table n Effect of idoxifene (IDOX) on cisplatin cytotoxicity in 41M/41McisR6 and CH1/
CHlcisR6 cels
96hIC5 (pM) 96hIC50 (M)
41M 4JMcisR6 Rvt CHI CH)ciR6 RP
Cisplatin 0.21 + 0.02 1.35 + 0.5 6.6 0.12 ± 0.02 0.71 _ 0.13 6.0
Cisplatin
+2 iLmIDOX 0.31±0.04 1.63±0.25 5.3 0.09±0.03 0.57±0.15 6.6
Values are mean±s.d. in three expriments. Rf, stance factor (IC. resistant line/IC,1
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Tae il Median effect analysis ofthe interaction between idoxifene
(IDOX) and cisplatin (CDDP) in 41M/41McisR6 and CHl/CHlasR6
cels
Molar ratio Combination
Cel line (CDDP-IDOX) index (Fa =0O.) Interaction
41M 1:2 1.5 0.6 Antagonistic
41McisR6 1:4 2.1 1.1 Antagonistic
CHI 1:4 0.76 ± 0.3 Additive/synergistic
CHlcisR6 1:6 0.95 ± 0.4 Additive
Values are mean ± s.d. in three experiments.
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comparative studies using two newly established acquired
doxorubicin-resistant human ovarian carcinoma cell lines
(shown to overexpress P-170 membrane glycoprotein) showed
that idoxifene (at a concentration of 2pM) is at least as
effective as verapamil or tamoxifen in reversing resistance. At
present, it is premature to make conclusions concerning the
achievable plasma and tumour levels of idoxifene in patients.
However, based on these preclinical data, idoxifene may also
confer useful clinical benefit in the multidrug resistance set-
ting.
We have also investigated whether idoxifene might possess
a therapeutic role in modulating the effects of cisplatin. We
have demonstrated non-cross-reistance to idoxifene (and
other tamoxifen analogues) in two acquired resistant lines
with contrasting mechanisms of resistance to cisplatin. In
common with the data of McClay and co-workers with
tamoxifen, weak synergism between cisplatin and idoxifene
was apparent for the parent CHI cell line. However, this
synergism was cell line dependent, with only additive effects
being observed for the CHlcisR6 line and antagonistic effects
being observed for the 41M and 4lMcisR6 lines. Interest-
ingly, McClay et al., 1993a) observed a degree of antagonism
in another melanoma cell line (Brown cell line) and in a
T-289 subline selected for resistance to tamoxifen.
Thus far, synergism between tamoxifen and cisplatin has
been demonstrated in vitro in three types of human tumour
cell line: malignant melanoma (T-289 cells, McClay et al.,
1992, 1993a), ovarian (2008 cells, McClay et al., 1993b;
primary ovarian tumour, Scambia et al., 1992) and small-cell
lung (UMC5 cells, McClay et al., 1993b). In common with
the above findings, our studies show that synergy is not
dependent on the presence of oestrogen receptors and, as
observed for a cisplatin-resistant variant of the T-289
melanoma line, the synergistic interaction is less for the
acquired cisplatin-resistant CH1 line than for its parent. Our
studies also demonstrate that the synergy observed (and the
antagonism observed for the 41M pair of lines) is not associ-
ated with two of the known main mechanisms of resistance
to cisplatin (reduced drug transport and enhanced removal of
platinum-induced DNA interstrand cross-links). This is in
agreement with the melanoma cell lie studies (McClay et al.,
1992, 1993a).
In addition to effects on oestrogen receptors, tamoxifen
has also been reported to exert other effects, notably on
calmodulin (Lam, 1984) and protein kinase C (O'Brian et al.,
1985). Moreover, calmodulin inhibitors, W-7 [(N-6amino-
hexyl)-5-chloro-1-naphthalenesulphonamideI and the clini-
cally used antipsychotic agent, trifluoperazine, have both
been shown to potentiate the cytotoxic effects of cisplatin in
vitro (Kikuhi et al., 1990; Perez et al., 1992a). In the
trifluoperazine plus cisplatin study, synergy was observed in
four of six cell lines by median effect analysis, while clear
antagonism was apparent in the remaining cell lines (Pere et
al., 1992a). Intriguingly, with the W-7 study, potentiation
appeared to be mediated through enhanced platinum uptake,
while with trifluoperazne a mechanism involving inhibition
of the incision step of DNA repair was proposed. In our
studies, however, the disparate results obtained by median
effect analysis did not appear to be related to either platinum
uptake or repair of platinum-DNA adducts (although it
should be noted that the DNA interstrand cross-links
measured by alklin elution only represent about 2% of the
total platinum-DNA adducts induced by cisplatin). Further-
more, the synergy observed in the T-289 melanoma cell line
did not appear to be related to effects on calmodulin (or
protein kinase C) (McClay et al., 1993a). Nevertheless, as
idoxifene is a more effective inhibitor of calmodulin than
tamoxifen (Rowlands et al., 1990), it remains conceivable
that the synergistic/antagonistic effects observed with cis-
platin in this study may be related to differential effects on
calmodulin. Alteratively, or in addition, effects mediated by
tamoxifen on so-called type II oestrogen binding sites may be
involved (Scambia et al., 1992).
In summary, idoxifene showed improved cytotoxicity com-
pared with tamoxifen in oestrogen receptor-negative human
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ovarian carcinoma cell lines. Based on data using acquired
doxorubicin- or cisplatin-resistant cell lines and combination
studies with cisplatin, idoxifene may confer useful clinical
benefit in combination therapy with doxorubicin and, for
some tumours, with cisplatin. However, further mechanistic
studies are necessary to elucidate the underlying basis of the
cell line-specific synergy or antagonism observed between
idoxifene and cisplatin.
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